Failing the public health - Rofecoxib, Merck, and the FDA

被引：407

作者：

Topol, EJ ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA

来源：

关键词：

D O I：

10.1056/NEJMp048286

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1707 / 1709

页数：3

共 3 条

[1] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
Bombardier, C
Laine, L
Reicin, A
Shapiro, D
Burgos-Vargas, R
Davis, B
Day, R
Ferraz, MB
Hawkey, CJ
Hochberg, MC
Kvien, TK
Schnitzer, TJ
Weaver, A
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
[2] Risk of cardiovascular events associated with selective COX-2 inhibitors
Mukherjee, D
Nissen, SE
Topol, EJ
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08): : 954 - 959
[3] A coxib a day won't keep the doctor away
Topol, EJ
Falk, GW
[J]. LANCET, 2004, 364 (9435) : 639 - 640